| 产品编号 | bs-103734P |
| 英文名称 | Recombinant Human VANGL2 Protein, N-His |
| 中文名称 | |
| 别 名 | STB1; VANGL2; Van Gogh-like protein 2; Loop-tail protein 1 homolog; KIAA1215; Vang-like protein 2; Strabismus 1 |
| 克 隆 号 | |
| 理论分子量 | 31.74 kDa |
| 性 状 | Lyophilized |
| 纯 度 | >90% as determined by SDS-PAGE. |
| 缓 冲 液 | Lyophilized from a solution in PBS pH 7.4, 0.02% NLS, 1mM EDTA, 4% Trehalose, 1% Mannitol. |
| 保存条件 | Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt. |
| 注意事项 | This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. |
| 产品介绍 |
The Vang family of proteins are integral membrane proteins that are homologs of the Drosophila tissue polarity gene strabismus. The gene encoding for Van Gogh-like protein 1 (Vangl1), also designated Strabismus 2 (STB2), localizes to chromosome 1p11-p13.1. Van Gogh-like protein 2 (Vangl2), also designated Strabismus1 (STB1), localizes on chromosome 1q22-q23. Vangl1 is expressed in testis and ovary, but also in gastric and pancreatic cancer. Vangl proteins play a key developmental role in establishing planar cell polarity (PCP) and in regulating convergent extension (CE) movements during embryogenesis. Vangl1 and Vangl2 are both down-regulated in several cancer cell lines and primary tumors.
Involved in the control of early morphogenesis and patterning of both axial midline structures and the development of neural plate. Plays a role in the regulation of planar cell polarity, particularly in the orientation of stereociliary bundles in the cochlea. Required for polarization and movement of myocardializing cells in the outflow tract and seems to act via RHOA signaling to regulate this process. SWISS: Q9ULK5 Gene ID: 57216 |
| 1、抗体溶解方法 | |
| 2、抗体修复方式 | |
| 3、常用试剂的配制 | |
| 4、免疫组化操作步骤 | |
| 5、免疫组化问题解答 | |
| 6、Western Blotting 操作步骤 | |
| 7、Western Blotting 问题解答 | |
| 8、关于肽链的设计 | |
| 9、多肽的溶解与保存 | |
| 10、酶标抗体效价测定程序 | |
